Lothar Jänsch

Prof. Dr. Lothar Jänsch

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2006 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
KTKathrin Thedieck
Kathrin Thedieck
THTorsten Hain
Torsten Hain
WMWalid Mohamed
Walid Mohamed
BTBrian J. Tindall
Brian J. Tindall
MNManfred Nimtz
Manfred Nimtz
LJLothar Jänsch
Lothar Jänsch
Summary: Pathogenic bacteria have to cope with defence mechanisms mediated by adaptive and innate immunity of the host cells. Cationic antimicrobial peptides (CAMPs) represent one of the most effective components of the host innate immune response. Here we establish the function of Lmo1695, a member of the VirR‐dependent virulence regulon, recently identified in Listeria monocytogenes. Lmo1695 encodes a membrane protein of 98 kDa with strong homology to the multiple peptide resistance factor (MprF) of Staphylococcus aureus. Like staphylococcal MprF, we found that Lmo1695 is involved in the synthesis of the membrane phospholipid lysylphosphatidylglycerol (L‐PG). In addition, Lmo1695 is also essential for lysinylation of diphosphatidylglycerol (DPG), another phospholipid widely distributed in bacterial membranes. A Δlmo1695 mutant lacking the lysinylated phospholipids was particularly susceptible to CAMPs of human and bacterial origin. The mutant strain infected both epithelial cells and macrophages only poorly and was attenuated for virulence when tested in a mouse model of infection. Lmo1695 is a member of a growing list of survival factors which enable growth of L. monocytogenes in different environments.

15 January 2007 in Journal of Bacteriology
Verified
Journal Article
Closed access
MBMaja BaumgärTner
Maja BaumgärTner
UKUwe KärSt
Uwe KärSt
BGBirgit Gerstel
Birgit Gerstel
MLMartin Loessner
Martin Loessner
JWJürGen Wehland
JürGen Wehland
LJLothar Jänsch
Lothar Jänsch
Lipoprotein anchoring in bacteria is mediated by the prolipoprotein diacylglyceryl transferase (Lgt), which catalyzes the transfer of a diacylglyceryl moiety to the prospective N-terminal cysteine of the mature lipoprotein. Deletion of thelgtgene in the gram-positive pathogenListeria monocytogenes(i) impairs intracellular growth of the bacterium in different eukaryotic cell lines and (ii) leads to increased release of lipoproteins into the culture supernatant. Comparative extracellular proteome analyses of the EGDe wild-type strain and the Δlgtmutant provided systematic insight into the relative expression of lipoproteins. Twenty-six of the 68 predicted lipoproteins were specifically released into the extracellular proteome of the Δlgtstrain, and this proved that deletion oflgtis an excellent approach for experimental verification of listerial lipoproteins. Consequently, we generated ΔlgtΔprfAdouble mutants to detect lipoproteins belonging to the main virulence regulon that is controlled by PrfA. Overall, we identified three lipoproteins whose extracellular levels are regulated and one lipoprotein that is posttranslationally modified depending on PrfA. It is noteworthy that in contrast to previous studies ofEscherichia coli, we unambiguously demonstrated that lipidation by Lgt is not a prerequisite for activity of the lipoprotein-specific signal peptidase II (Lsp) inListeria.

1 August 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
DLDaniel Lang
Daniel Lang
BSBjörn H Schott
Björn H Schott
MHMarco Van Ham
Marco Van Ham
LMLorena Morton
Lorena Morton
LKLeonora Kulikovskaja
Leonora Kulikovskaja
IDIldiko Rita Dunay
Ildiko Rita Dunay
Chronic infection with the neurotropic parasite Toxoplasma gondii has been implicated in the risk for several neuropsychiatric disorders. The mechanisms, by which the parasite may alter neural function and behavior of the host, are not yet understood completely. Here, a novel proteomic approach using mass spectrometry was employed to investigate the alterations in synaptic protein composition in a murine model of chronic toxoplasmosis. In a candidate-based strategy, immunoblot analysis and immunohistochemistry were applied to investigate the expression levels of key synaptic proteins in glutamatergic signaling. A comparison of the synaptosomal protein composition revealed distinct changes upon infection, with multiple proteins such as EAAT2, Shank3, AMPA receptor, and NMDA receptor subunits being downregulated, whereas inflammation-related proteins showed an upregulation. Treatment with the antiparasitic agent sulfadiazine strongly reduced tachyzoite levels and diminished neuroinflammatory mediators. However, in both conditions, a significant number of latent cysts persisted in the brain. Conversely, infection-related alterations of key synaptic protein levels could be partly reversed by the treatment. These results provide evidence for profound changes especially in synaptic protein composition in T. gondii-infected mice with a downregulation of pivotal components of glutamatergic neurotransmission. Our results suggest that the detected synaptic alterations are a consequence of the distinct neuroinflammatory milieu caused by the neurotropic parasite.

23 June 2017 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
HLHolger Lingel
Holger Lingel
JWJosef Wissing
Josef Wissing
AAAditya Arra
Aditya Arra
DSDenny Schanze
Denny Schanze
SLStefan Lienenklaus
Stefan Lienenklaus
MBMonika Christine Brunner-Weinzierl
Monika Christine Brunner-Weinzierl
The blockade of inhibitory receptors such as CTLA-4 (CD152) is being used as immune-checkpoint therapy, offering a powerful strategy to restore effective immune responses against tumors. To determine signal components that are induced under the control of CTLA-4 we analyzed activated murine CD8+ T cells by quantitative proteomics. Accurate mass spectrometry revealed that CTLA-4 engagement led to central changes in the phosphorylation of proteins involved in T-cell differentiation. Beside other targets, we discovered a CTLA-4-mediated induction of the translational inhibitor programmed cell death-4 (PDCD4) as a result of FoxO1 nuclear re-localization. PDCD4 further bound a distinct set of mRNAs including Glutaminase, which points out a critical role for CTLA-4 in CD8+ T-cell metabolism. Consequently, PDCD4-deficient cytotoxic T-lymphocytes (CTLs) expressed increased amounts of otherwise repressed effector molecules and ultimately led to superior control of tumor growth in vivo. These findings reveal a novel CTLA-4-mediated pathway to attenuate CTLs and indicate the importance of post-transcriptional mechanisms in the regulation of anti-tumor immune responses.

17 June 2025 in Cell
Verified
Journal Article
Open access
MWMarcel S. Woo
Marcel S. Woo
JBJohannes Brand
Johannes Brand
LBLukas C. Bal
Lukas C. Bal
MMManuela Moritz
Manuela Moritz
MWMark Walkenhorst
Mark Walkenhorst
MFManuel A. Friese
Manuel A. Friese
Inflammation, aberrant proteostasis, and energy depletion are hallmarks of neurodegenerative diseases such as multiple sclerosis (MS). However, the interplay between inflammation, proteasomal dysfunction in neurons, and its consequences for neuronal integrity remains unclear. Using transcriptional, proteomic, and functional analyses of proteasomal subunits in inflamed neurons, we found that interferon-γ-mediated induction of the immunoproteasome subunit, proteasome 20S beta 8 (PSMB8) impairs the proteasomal balance, resulting in reduced proteasome activity. This reduction causes the accumulation of phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key metabolic regulator, leading to enhanced neuronal glycolysis, reduced pentose phosphate pathway activity, oxidative injury, and ferroptosis. Neuron-specific genetic and systemic pharmacological targeting of PSMB8 or PFKFB3 protected neurons in vitro and in a mouse model of MS. Our findings provide a unifying explanation for proteasomal dysfunction in MS and possibly other neurodegenerative diseases, linking inflammation to metabolic disruption, and presenting an opportunity for targeted neuroprotective therapies.

1 August 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JVJenny Voigt
Jenny Voigt
DMDavid F.G. Malone
David F.G. Malone
JDJoana Dias
Joana Dias
ELEdwin Leeansyah
Edwin Leeansyah
NBNiklas Björkström
Niklas Björkström
LJLothar Jänsch
Lothar Jänsch